


0590

OKSD

0129

BIOTECHNOLOGY
SYSTEMS
BRANCH

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/010,184
Source: DIPE
Date Processed by STIC: 12/24/2001

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE **CHECKER VERSION 3.1 PROGRAM**, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by the treatment given to all mail coming via the Brentwood Mail Facility.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom, including:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
1911 South Clark Street, Crystal Mall One, Sequence Information, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, 2011 South Clark Place, Customer Window, Box Sequence, Crystal Plaza Two,
Lobby, Room 1B03, Arlington, Virginia 22202
4. Federal Express Delivery, 2011 South Clark Street, Crystal Plaza 2, Room 1B03-Mailroom, Box Sequence,
Arlington, VA 22202

BEST AVAILABLE COPY

Raw Sequence Listing Error Summary

ERROR DETECTED

SUGGESTED CORRECTION

SERIAL NUMBER:

1e/010,184

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics
 Wrapped Aminos The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2 Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3 Misaligned Amino
 Numbering The numbering under each 5' amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4 Non-ASCII The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5 Variable Length Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6 PatentIn 2.0
 "bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7 Skipped Sequences
 (OLD RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:
 (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
 (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
 (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
 This sequence is intentionally skipped

 Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8 Skipped Sequences
 (NEW RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence.
 <210> sequence id number
 <400> sequence id number
 000
- 9 Use of n's or Xaa's
 (NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
 Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
 In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 10 Invalid <213>
 Response Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
- 11 Use of <220> Sequence(s) 5,8 missing the <220> "Feature" and associated numeric identifiers and responses.
 Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
 (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12 PatentIn 2.0
 "bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13 Misuse of n n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

OIPE

RAW SEQUENCE LISTING

DATE: 12/21/2001

PATENT APPLICATION: US/10/010,184

TIME: 08:45:55

Input Set : A:\7087.ST25.txt

Output Set: N:\CRF3\12212001\J010184.raw

3 <110> APPLICANT: Bristol-Myers Squibb Pharma Company
 4 Priestly, et al.
 6 <120> TITLE OF INVENTION: Novel Lactam Inhibitors of Hepatitis C Virus NS3 Protease
 8 <130> FILE REFERENCE: PH-7087-A
 C--> 10 <140> CURRENT APPLICATION NUMBER: US/10/010,184
 C--> 10 <141> CURRENT FILING DATE: 2001-12-06
 10 <150> PRIOR APPLICATION NUMBER: US 09/626,286
 11 <151> PRIOR FILING DATE: 2000-07-25
 13 <160> NUMBER OF SEQ ID NOS: 8
 15 <170> SOFTWARE: PatentIn version 3.1
 17 <210> SEQ ID NO: 1
 18 <211> LENGTH: 6
 19 <212> TYPE: PRT
 20 <213> ORGANISM: Artificial Sequence
 22 <220> FEATURE:
 23 <223> OTHER INFORMATION: The synthesis of this peptide may be performed on an ABI 43A
 pept
 24 ide synthesizer using readily available materials well known to o
 25 rdinarily skilled artisans
 27 <220> FEATURE:
 28 <221> NAME/KEY: ACT_SITE
 29 <222> LOCATION: (1)..(1)
 30 <223> OTHER INFORMATION:
 33 <220> FEATURE:
 34 <221> NAME/KEY: misc_feature
 35 <222> LOCATION: (3)..(3)
 36 <223> OTHER INFORMATION: diphenylalanine
 39 <220> FEATURE:
 40 <221> NAME/KEY: misc_feature
 41 <222> LOCATION: (5)..(5)
 42 <223> OTHER INFORMATION: cyclohexylalanine
 45 <400> SEQUENCE: 1
 w 47 Asp Glu Xaa Glu Xaa Cys
 48 1 5
 51 <210> SEQ ID NO: 2
 52 <211> LENGTH: 6
 53 <212> TYPE: PRT
 54 <213> ORGANISM: Artificial Sequence
 56 <220> FEATURE:
 57 <223> OTHER INFORMATION: The synthesis of this peptide may be performed on an ABI 43A
 pept
 58 ide synthesizer using readily available materials well known to o
 59 rdinarily skilled artisans
 61 <220> FEATURE:
 62 <221> NAME/KEY: MOD_RES
 63 <222> LOCATION: (1)..(1)
 64 <223> OTHER INFORMATION: Acetylation
 67 <220> FEATURE:

Does Not Comply
 Corrected Diskette Needed

pp 3-4

```
68 <221> NAME/KEY: misc_feature
```

RAW SEQUENCE LISTING

DATE: 12/21/2001

PATENT APPLICATION: US/10/010,184

TIME: 08:45:55

Input Set : A:\7087.ST25.txt

Output Set: N:\CRF3\12212001\J010184.raw

69 <222> LOCATION: (2)..(2)
 70 <223> OTHER INFORMATION: D-Aspartic Acid
 73 <400> SEQUENCE: 2
 75 Asp Xaa Ile Val Pro Cys
 76 1 5
 79 <210> SEQ ID NO: 3
 80 <211> LENGTH: 5
 81 <212> TYPE: PRT
 82 <213> ORGANISM: Artificial Sequence
 84 <220> FEATURE:
 85 <223> OTHER INFORMATION: The synthesis of this peptide may be performed on an ABI 43A
 pept
 86 ide synthesizer using readily available materials well known to o
 87 rdinarily skilled artisans
 89 <400> SEQUENCE: 3
 91 Met Gly Ala Gln His
 92 1 5
 95 <210> SEQ ID NO: 4
 96 <211> LENGTH: 15
 97 <212> TYPE: PRT
 98 <213> ORGANISM: Artificial Sequence
 100 <220> FEATURE:
 101 <223> OTHER INFORMATION: The synthesis of this peptide may be performed on an ABI 43A
 pept
 102 ide synthesizer using readily available materials well known to o
 103 rdinarily skilled artisans
 105 <400> SEQUENCE: 4
 107 Met Arg Gly Ser His His His His His His Met Gly Ala Gln His
 108 1 5 10 15
 111 <210> SEQ ID NO: 5
 112 <211> LENGTH: 6
 113 <212> TYPE: PRT
 114 <213> ORGANISM: Artificial
 116 <220> FEATURE:
 117 <221> NAME/KEY: misc_feature
 118 <222> LOCATION: (6)..(6)
 119 <223> OTHER INFORMATION: 2-amino-4-penten-boronic acid
 122 <400> SEQUENCE: 5
 124 Asp Glu Val Val Pro Xaa
 125 1 5
 128 <210> SEQ ID NO: 6
 129 <211> LENGTH: 5
 130 <212> TYPE: PRT
 131 <213> ORGANISM: Artificial Sequence
 133 <220> FEATURE:
 134 <223> OTHER INFORMATION: The synthesis of this peptide may be performed on an ABI 43A
 pept
 135 ide synthesizer using readily available materials well known to o
 136 rdinarily skilled artisans
 138 <220> FEATURE:
 139 <221> NAME/KEY: ACETYLATION
 140 <222> LOCATION: (1)..(1)

see item 11 on Error Summary Sheet

RAW SEQUENCE LISTING

DATE: 12/21/2001

PATENT APPLICATION: US/10/010,184

TIME: 08:45:55

Input Set : A:\7087.ST25.txt

Output Set: N:\CRF3\12212001\J010184.raw

141 <223> OTHER INFORMATION: Acetylation

144 <220> FEATURE:

145 <221> NAME/KEY: AMIDATION

146 <222> LOCATION: (5)..(5)

147 <223> OTHER INFORMATION: para-nitroaniline

150 <400> SEQUENCE: 6

152 Asp Glu Glu Ala Cys

153 1 5

156 <210> SEQ ID NO: 7

157 <211> LENGTH: 23

158 <212> TYPE: PRT

159 <213> ORGANISM: Artificial Sequence

161 <220> FEATURE:

162 <223> OTHER INFORMATION: The synthesis of this peptide may be performed on an ABI 43A
pept

163 ide synthesizer using readily available materials well known to o

164 rdinarily skilled artisans

166 <400> SEQUENCE: 7

168 Lys Lys Gly Ser Val Val Ile Val Gly Arg Ile Val Leu Ser Gly Lys

169 1 5 10 15

172 Pro Ala Ile Ile Pro Lys Lys

173 20

176 <210> SEQ ID NO: 8

177 <211> LENGTH: 9

178 <212> TYPE: PRT

C--> 179 <213> ORGANISM: Artificial *see item 11*

181 <220> FEATURE:

182 <221> NAME/KEY: ACETYLATION

183 <222> LOCATION: (1)..(1)

184 <223> OTHER INFORMATION: acetyl group

187 <220> FEATURE:

188 <221> NAME/KEY: MOD_RES

189 <222> LOCATION: (3)..(3)

190 <223> OTHER INFORMATION: Aspartic acid modified with EDANS, 5-[(2'-aminoethyl)amino]
naphth

191 ylene sulfonic acid

194 <220> FEATURE:

195 <221> NAME/KEY: MISC_FEATURE

196 <222> LOCATION: (6)..(6)

197 <223> OTHER INFORMATION: 2-amino butyric acid bonded through an ester group

200 <220> FEATURE:

201 <221> NAME/KEY: MOD_RES

202 <222> LOCATION: (9)..(9)

203 <223> OTHER INFORMATION: Lysine modified by DabcyL; 4-[[4'(dimethylamino)phenyl]azo]
benzoi

204 c acid

207 <400> SEQUENCE: 8

209 Asp Glu Asp Glu Glu Xaa Ala Ser Lys

210 1 5

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/010,184

DATE: 12/21/2001

TIME: 08:45:56

Input Set : A:\7087.ST25.txt

Output Set: N:\CRF3\12212001\J010184.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application No
L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:47 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:75 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2
L:114 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:5
L:124 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:179 M:220 C: Keyword misspelled or invalid format, <213> ORGANISM for SEQ ID#:8
L:209 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8